Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16374937 | 0.89 | SMYD3 (0.49) | SMYD3MAOAGAA | |
| SCHEMBL21198215 | 0.89 | SMYD3 (0.49) | SMYD3MAOAGAA | |
| SCHEMBL21213732 | 0.89 | SMYD3 (0.49) | SMYD3MAOAGAA | |
| Trifluoroacetic Acid SCHEMBL3154236 | 0.86 | MME (0.39) | CCR2MAOABTKDPP4DPP8 | |
| SCHEMBL3154242 | 0.81 | PKM (0.43) | MAOAGAAEPHX1 | |
| SCHEMBL4191188 | 0.80 | MAOA (0.47) | MAOAGAAEPHX1 | |
| Trifluoroacetic Acid SCHEMBL3150147 | 0.80 | SMYD3 (0.38) | SMYD3 | |
| Trifluoroacetic Acid SCHEMBL852782 | 0.78 | SMYD3 (0.41) | SMYD3CCR2DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL14657132 | 0.78 | SMYD3 (0.41) | SMYD3CCR2DPP4DPP8 | |
| SCHEMBL12819982 | 0.76 | MAOA (0.42) | MAOAGAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | SMYD3 4852/4885CCR2 586/4885MAOA 128/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | SMYD3 4067/4885CCR2 410/4885MAOA 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.